Anakinra

Chemical formula: C₂₀H₂₃N₅O₇S₂  Molecular mass: 509.6 g/mol 

Active ingredient description

Anakinra neutralises the biologic activity of interleukin-1α (IL-1α) and interleukin-1β (IL-1β) by competitively inhibiting their binding to interleukin-1 type I receptor (IL-1RI). Interleukin-1 (IL-1) is a pivotal pro-inflammatory cytokine mediating many cellular responses including those important in synovial inflammation.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
L04AC03 Anakinra L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC03

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
KINERET Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

3D molecular structure

3D representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 143090-92-0
DrugBank Drug: DB00026
KEGG Drug: D02934
RxNorm Ingredient: 72435
SNOMED-CT Concept: 385549000
Anakinra (substance)
UNII Identifier: 9013DUQ28K
ANAKINRA

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.